Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it
US6995163B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 2, 2004 |
| Grant date | Feb 7, 2006 |
| Priority date | — |
| Expiry date | Dec 16, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof, wherein R2 is a hydrogen atom, etc.; R3 is a hydrogen atom, etc.; M′ represents a hydrogen atom, a halogen atom or a C1-6 alkyl group; R7′ represents a hydrogen atom or a C1-6 alkyl group; and W′ represents a phenyl group, pyridyl group, thienyl group, or furyl group, each being optionally substituted; and a pharmacologically acceptable salt thereof or hydrates thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.